$370,000.00 in Sales Expected for Flex Pharma Inc (FLKS) This Quarter

Analysts expect that Flex Pharma Inc (NASDAQ:FLKS) will report sales of $370,000.00 for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Flex Pharma’s earnings. The highest sales estimate is $400,000.00 and the lowest is $320,000.00. Flex Pharma posted sales of $300,000.00 during the same quarter last year, which suggests a positive year-over-year growth rate of 23.3%. The business is expected to issue its next earnings report on Wednesday, March 14th.

According to Zacks, analysts expect that Flex Pharma will report full-year sales of $370,000.00 for the current year, with estimates ranging from $1.32 million to $1.40 million. For the next financial year, analysts forecast that the company will post sales of $3.75 million per share, with estimates ranging from $1.41 million to $5.43 million. Zacks’ sales calculations are a mean average based on a survey of analysts that cover Flex Pharma.

Flex Pharma (NASDAQ:FLKS) last released its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.60) by $0.06. The firm had revenue of $0.41 million for the quarter, compared to analyst estimates of $0.47 million. Flex Pharma had a negative net margin of 2,655.19% and a negative return on equity of 71.39%.

Several brokerages have commented on FLKS. Zacks Investment Research upgraded shares of Flex Pharma from a “hold” rating to a “buy” rating and set a $3.75 price target on the stock in a research note on Tuesday, October 3rd. Cantor Fitzgerald restated a “hold” rating and issued a $10.00 price target on shares of Flex Pharma in a research note on Monday, November 6th. Roth Capital restated a “buy” rating and issued a $12.00 price target on shares of Flex Pharma in a research note on Wednesday, January 3rd. Finally, Ladenburg Thalmann Financial Services began coverage on shares of Flex Pharma in a research note on Thursday. They issued a “buy” rating and a $12.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $9.79.

An institutional investor recently raised its position in Flex Pharma stock. Ameriprise Financial Inc. raised its position in Flex Pharma Inc (NASDAQ:FLKS) by 10.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 720,524 shares of the biotechnology company’s stock after purchasing an additional 65,699 shares during the quarter. Ameriprise Financial Inc. owned about 4.01% of Flex Pharma worth $2,457,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 27.26% of the company’s stock.

Flex Pharma (NASDAQ:FLKS) traded up $0.37 on Friday, reaching $4.39. 176,500 shares of the company traded hands, compared to its average volume of 87,276. The firm has a market capitalization of $78.90 and a price-to-earnings ratio of -2.17. Flex Pharma has a 52-week low of $2.68 and a 52-week high of $5.93.

COPYRIGHT VIOLATION WARNING: This article was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.com-unik.info/2018/01/25/370000-00-in-sales-expected-for-flex-pharma-inc-flks-this-quarter.html.

Flex Pharma Company Profile

Flex Pharma, Inc is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms.

Get a free copy of the Zacks research report on Flex Pharma (FLKS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Flex Pharma (NASDAQ:FLKS)

Receive News & Ratings for Flex Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flex Pharma and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit